In recent years, molecularly targeted therapeutic drugs have been used in a large number of clinical applications, such as lung cancer, liver cancer, kidney cancer, intestinal cancer, head and neck tumors, etc. Molecular targeted therapy is a new biological treatment mode that acts on cell signaling pathways, proto-oncogenes or oncogenes, tumor blood vessel formation, etc., to reverse this malignant biological behavior at the molecular level, thus inhibiting the growth of tumor cells or even making them fade away completely. Molecularly targeted drugs have relatively high concentration in tumor site, can stay for a long time and have strong killing activity on tumor target cells. However, their high concentration in blood, with the above advantages, still have some adverse effects, such as rash, diarrhea, drug-related edema, etc. These adverse effects bring great pain to patients, forcing them to reduce the dosage or even cause discontinuation of the drug. Targeted therapy drugs such as erlotinib, gefitinib, and erlotinib can cause itching and congestion of the skin, and a few patients may have skin breakdown with desquamation, oozing, and possible secondary infection, adding to the suffering of patients. Chinese medicine has received satisfactory results by identifying and treating the disease from the pathogenesis of spleen deficiency, phlegm-dampness, blood heat and wind, and heat and toxicity congestion. Chinese medicine prescribes drugs on the basis of evidence-based treatment, and uses Chinese medicine together with molecular targeting therapy drugs, which not only can reduce the adverse effects of drugs, but also increase their efficacy, and play a great advantage in increasing the effectiveness and reducing toxicity. Patients who have obvious adverse reactions should be promptly seen in the outpatient clinic.